Warfarin Therapy in Acute Coronary Syndromes
نویسندگان
چکیده
منابع مشابه
Prognostic value of C-Reactive Protein in Acute Coronary Syndromes
Introduction: Coronary artery disease (CAD) is among the most common, serious, chronic and life- threatening illnesses in the world. CAD represents a spectrum of conditions, with acute myocardial infarction at one end of it and silent ischemia at the other. There is growing evidence on importance of prognosis of C- reactive protein (CPR) in unstable angina and this protein is a maker of an adve...
متن کاملStatin Therapy in Acute Coronary Syndromes
Randomized trials have established that statin treatment reduces coronary events in primary prevention and in patients with stable coronary artery disease. In unstable coronary artery disease, however, the pathophysiological background is distinct, and the potential benefits of statin therapy have not been evaluated until recently. Data from animal models and clinical studies indicate that stat...
متن کاملAntiplatelet therapy in acute coronary syndromes.
INTRODUCTION Coronary thrombosis is a frequent cause of death and myocardial infarction most often explained by superimposition of a platelet-rich thrombus on existing coronary artery disease. Therefore, antiplatelet drugs are essential in the treatment and secondary prevention of acute coronary syndromes (ACS) and during percutaneous coronary intervention. Several novel antiplatelet drugs are ...
متن کاملAnticoagulant Therapy in Acute Coronary Syndromes with Focus on Fondaparinux ACUTE CORONARY SYNDROMES | REVIEW
In this context, bleeding is the most frequent non-ischaemic complication observed in ACS. It has a strong impact on the outcome, with a dosedependent association between bleeding and risk of death or other ischaemic events. Major bleeding was shown to be associated with a four-fold increase in the risk of death, a five-fold increase in the risk of recurrent MI and a three-fold increase in the ...
متن کاملAntiplatelet therapy in acute coronary syndromes: focus on ticagrelor
The use of antiplatelet agents, specifically the thienopyridines, has become a standard of care in the approach to the patient presenting with an acute coronary syndrome. These drugs irreversibly inhibit the platelet by permanently binding to the surface P2Y12 receptor and blocking the downstream fibrinogen cross-linking between platelets, which leads to aggregation and thrombus. However, curre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Heart Drug
سال: 2002
ISSN: 1422-9528,1424-0556
DOI: 10.1159/000066026